Thumbtack and Redfin Predict Top Home Trends for 2026

Hologic and Biotheranostics will present 11 studies at the 2025 San Antonio Breast Cancer Symposium that demonstrate the potential expanded utility of the Breast Cancer Index Test. The test can predict which patients will benefit from extended endocrine therapy and may identify premenopausal patients at minimal risk of distant recurrence. The studies explore the test's performance in diverse patient subgroups and sample types, including premenopausal women and comparison to the 21-gene assay for extended endocrine therapy treatment decisions.